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PROGRAM REPORT 

The Center of Excellence in Livestock Diseases and Human Health was created in 1984 
to promote interdisciplinary activities designed to: 
• 	 Improve the quality of human life through better animal health. 
• 	 Augment livestock disease research capabilities in the College of Veterinary 
Medicine and the Institute of Agriculture. 
• 	 Identify and characterize animal diseases that are analogous to human diseases 
(animal models of human disease). 
• 	 Develop new strategies for the diagnosis, treatment, and prevention of disease. 
Since its inception, the Center has successfully promoted these goals by serving to 
promote the development of programs that impact the understanding and 
treatment/prevention of livestock and human diseases. The objectives have evolved and 
now represent a predominant, contemporary concentration on molecular and cellular 
approaches to investigations supporting the general areas of infectious 
diseases/population medicine, toxicology, reproduction, host defense, molecular genetics, 
and carcinogenesis. All of the Center core faculty contribute to at least one of these areas 
of emphasis. The Center promotes the potential of new investigators to develop 
competitive research programs and facilitates the efforts of established investigators to 
maintain and expand their research efforts. In addition, the Center actively supports the 
training of graduate students, veterinary student interns, and postdoctoral research 
students. 
Center accomplishments for the year 2000-2001 were excellent when measured both as 
benchmarks (Table 1) and, perhaps more significantly, as the increasing extramural 
funding base (Table 2). The return on the State's investment in the Center as the 
ratio of expenditures from extramural grants and contracts to Center appropriation 
was 4.4. Grant and contract expenditures exceeded $2.5 million (Table 2). While 
this was impressive, the increase in total award funding supporting Center faculty 
increased from $10,863,253 the preceding year to $12,760,303, approximately 
$2,000,000. This increase was due primarily to significant new grants and contracts 
awarded to Drs. McEntee, Rouse, and S. Oliver, although other new valuable grants 
and contracts were awarded to Center faculty. The 16 Center faculty averaged 
approximately 5 scientific and scholarly publications (74 total) and 3 invited 
presentations (48 total) at regional and prestigious national meetings (Table 1). 
This report features the accomplishments and activities of investigators and research 
teams that constitute the core of the Center. Their achievements serve a crucial function 
in promoting the College of Veterinary Medicine, the Institute of Agriculture, and the 
University of Tennessee. Furthermore, they continue to ensure that the Center maintains 
its strong competitive position and contributes to the fiscal health of our research 
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environment. The report endeavors to emphasize the strength of the Center and give a 
clear indication of how it meets its objectives. 
Research Funding 
Important goals of the Center of Excellence in Livestock Diseases and Human Health are 
to support researchers and to promote research by a variety of mechanisms. State fiscal 
restraints for several years have restricted our ability to recruit and hire competitive 
researchers. The Center has had a significant impact over the last three years in 
recruitment of researchers with ongoing research programs. The existence of the 
Center and its ability to contribute to start-up packages has made the difference in 
these recruitment efforts. The Center does not serve as a primary source of research 
funding for faculty. The main criteria used for funding proposals include scientific merit, 
likelihood of leading to extramural funding and relevance to the Center's objectives. 
Proposals submitted to the Center for funding are reviewed by the Research and Graduate 
Programs Advisory Committee. The latter has one representative from every department 
of the College of Veterinary Medicine. For 2000-2001, "seed" grant funds totaling 
$288,550 were awarded to promote research initiatives by Center faculty. 
The following projects were supported this past year by the Center: 
• 	 Dr. Frank Andrews. Pathogenesis of acid injury in the non-glandular 
region of the equine stomach. 
• 	 Dr. David Brian. Genetic structural elements regulating RNA synthesis 
during coronavirus replication. 
• 	 Dr. Mei-Zhen Cui. Mechanisms of lipoprotein induction of tissue factor 
gene expression in smooth muscle cells. 
• 	 Dr. James Godkin. Retinoids in oocyte maturation and embryonic 
development. 
• 	 Dr. Alan Mathew. Characterization of bacterial resistance elements in 
swine herds. 
• 	 Dr. Michael McEntee. Cellular mechanisms of NSAID-mediated 
regression in intestinal tumors. 
• 	 Dr. John New. A pilot project to survey rodent populations in the Great 
Smoky Mountains National Park for the presence of hantavirus and 
Borrelia species. 
• 	 Dr. Jack Oliver. Studies of tall fescue toxin-induced aminoacidemia in 
cattle. 
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• 	 Dr. Steve Oliver. Identification and characterization of streptococcal 
virulence factors. 
• 	 Dr. Barry Rouse. Role of chaperone-bound peptides in the induction of 
antiviral CTL responses. 
• 	 Dr. Hildegard Schuller. Effects of NNK on beta-adrenergic growth 
regulation of pulmonary adenocarcinoma in vitro. 
• 	 Dr. Terry Schultz. Quantification of the underestimation of toxic 
potency in micro scale testing. 
• 	 Dr. Patricia Tithof. Effects of components of cigarette smoke on 
endothelial cell and vascular smooth muscle cell arachidonic acid 
metabolism and apoptosis. (start-up grant) 
• 	 Dr. Hwa-Chain Wang. Novel intracellular signaling pathways leading to 
cell quiescence and apoptosis. (start-up grant) 
• 	 Dr. Xuemin Xu. Untitled start-up grant. 
Equipment and Facilities 
The Center promotes the research infrastructure of the CVM and the Institute of 
Agriculture by participating in the purchase and maintenance of essential research 
equipment and through maintenance and renovation of research facilities. Criteria 
considered in the allocation of these funds include justification of need, equipment 
availability, and the number of investigators who may benefit. Requests from 5 
individual investigators for 5 pieces of equipment totaling $35,398 were funded by the 
Center this past year. Researchers benefiting from these equipment grants were Drs. 
Wang, S. Oliver, Bartges, Rouse, and Brian. In addition, Dr. Hildegard Schuller and 
other COE faculty secured a substantial equipment grant from the NIH ($150,000, Table 
2) with matching funds ($111 ,448) provided by the Center. This grant supported the 
purchase of a state-of-the-art Fascan-Cell SorterlFlow Cytometer which is being used in 
support of basic and clinical research projects. Moreover, the Center is providing 
technical support for this sophisticated instrument. Matching funds and technical 
support provided by the Center were critical in the success of this application. This 
"turbosorter" greatly enhances the research capacity and grant competitiveness of the 
Center faculty and is being used also by investigators not previously associated with the 
Center. 
Renovations funded by the Center of Excellence included extensive repair and renovation 
of walk-in coolers in A329A and A307 laboratories in the Veterinary Teaching Hospital. 
These coolers are used primarily by investigators participating in the COE. Similarly, 
repair and maintenance of several pieces of research equipment were funded by COE 
funds. This included an ultracentrifuge and the transmission electron microscope. 
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Research Training and Student Awards 
The College of Veterinary Medicine funds at least 10 positions for Ph.D. training of 
students with a professional medical degree. Some of these positions are based in the 
Department of Pathology (as part of their residency/PhD program) and some are awarded 
without restriction. Most of these students become linked with Center of Excellence 
faculty. These young investigators significantly bolster the achievements of the Center. 
Faculty benefiting from these graduate students include Drs. Brian, Tithof, Schuller and 
Wang. 
An important mechanism by which the Center of Excellence promotes biomedical 
research is to provide summer opportunities for veterinary students to do investigational 
work in research laboratories in the College of Veterinary Medicine. This past year the 
Center funded nine requests from first- and second-year students. The students are 
required to provide a summary of their work, which then is entered into a competition 
judged by Phi Zeta, the veterinary honorary society. This program is very successful. 
Several students have presented their work at national scientific meetings, and numerous 
manuscripts detailing results from work done by these students have been submitted for 
publication to refereed journals. In fact, over the past five years, this program has 
resulted in approximately 30 publications in refereed journals, several with the 
students as senior authors. The following veterinary student interns and their (mentors) 
and proj ects were supported by the Center during the summer of 200 1 : 
• 	 Eric Rundlett (Dr. Davis), "Determining Antibiotic Resistance in Cattle in a 
Developing Country". 
• 	 Michael Owston (Drs. Bemis and Kania), "Bacterial Gene Expression". 
• 	 Lisa Miller (Drs. Lane, Bartges, and Mawby), "Urinary Tract Disorders and 
Hypothyroidism in Doberman Pinschers, Golden Retrievers, and Labrador 
Retrievers" . 
• 	 Pam Wilkins (Drs. Patton and Faulkner), "Diagnosis of Gastrointestinal Parasites 
in Free-ranging African Gorillas". 
• 	 Jan McGinn (Dr. Tithof), "Identification of Specific Components of Cigarette 
Smoke that Cause Vascular Smooth Muscle Death". 
• 	 Shannon Jarchow (Dr. Schultz), "Quantification of Thyroid Disruption by Micro 
scale Testing". 
• 	 Kara Poucher (Dr. Kennedy), "Feline Coronavirus in Nondomestic Felidae". 
• 	 Adrienne Lickey (Dr. Ramsay), "Disease Survey of Domestic Cats III 
Guatemala: Potential Health Risks to New World Felids". 
• 	 Chuck Bane (Dr. Reed), "Gross Anatomy of the Gray Short-tailed Opossum". 
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Personnel Changes 
Dr. Michael Blackwell assumed the position of Dean of the College of Veterinary 
Medicine at the . beginning of the fiscal year. He continued the practice of the two 
preceding Dean's by serving as the Director of the Center for the year. Operation of the 
Center remained under the supervision of the Assistant Director, Dr. Leon Potgieter, 
Professor and Head of Comparative Medicine, who also served as Director of the 
Comparative and Experimental Medicine graduate program (CEM). Effective at the 
beginning of the next fiscal year, Dean Blackwell appointed Dr. Robert Moore, Professor 
and Head of Microbiology, as the Director of the Center and of the CEM program. Dr. 
Potgieter led the Center ably for the past several years and is congratulated for promoting 
its highly successful status. 
Recent recruitments of faculty with a significant research focus will benefit the Center of 
Excellence in the future. Over the past approximately three years we have recruited eight 
new researchers that will or are contributing to our Center of Excellence. They include 
Dr. Hwa Chain Wang (Comparative Medicine Department) who is well funded by NIH 
and Dr. Patricia Tithoff (Animal Science) who has received very competitive scores for 
her proposals and likely will be funded by NIH in the future. Dr. Joseph W. Bartges 
(Department of Small Animal Clinical Sciences) has received substantial funding from a 
variety of industry sources and the Morris Animal Foundation. Dr. David Slauson, 
former head of the Department of Pathology, recruited Drs. Xuemin Xu and Mei-Zhen 
Cui. They brought with them significant research funding from NIH (ROI grants), 
American Heart Association and foundations. Their research interests also fall within the 
Center's focus. Dr. Hildegard Schuller, the current acting Head of Pathology, recruited 
Dr. Howard Plummer whose interest in cell regulation in carcinogenesis and asthma will 
complement other investigators in the Center. In addition a search is underway to fill a 
Pathology faculty position with an investigator with established interests in cancer 
research. Dr. Pam Small joined Microbiology this past year as an internationally 
recognized expert in the area of molecular pathogenesis of mycobacterial diseases, 
significant problems for human health and cattle industry. Dr. Small was awarded 
significant NIH grant support almost immediately and will join the Center as a core 
faculty member in 2001-2002. As her work expands into the area of tuberculosis 
research, she will do a large portion of her work in the biosafety level 3 core facility in 
the Veterinary Teaching Hospital. 
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Center Faculty Reports 
Following are the reports from the core faculty of the Center. For organizational 
purposes the reports are grouped into the two umbrella aspects of the Center's interests, 
programs directly applicable to livestock health and population medicine and programs 
involving animal and laboratory models applicable to disease. 
Livestock Diseases, Population Medicine, and Reproduction 
Dr. Frank M. Andrews (equine gastritis) 
Collaborators, staff and graduate students: Dr. A.G. Mathew, Dr. C.S. Patton, Dr. J.T. 
Blackford, Dr. A.M. Saxton, Dr. S. Murphy, Dr. J. Collins, Dr. R. Torres-Diaz, M. 
Sewell, A. Nadeau 
Dr. Andrews studies the pathogenesis and mechanisms of gastric ulcer development in a 
horse model. Equine gastric ulcer disease (EGUS) is common in horses and has been 
implicated in poor performance with significant economic impact on the horse industry. 
Performance horses are commonly fed concentrated high-energy feeds that contain high 
levels of carbohydrates (starches). These carbohydrates undergo fermentation by resident 
bacteria in the stomach that may result in a low stomach pH and release of by-products 
such as volatile fatty acids (VFA; acetic, propionic, butyric, and valeric acids). Previous 
research in this laboratory established that high concentrations of VF As are produced in 
the stomach of horses fed high-energy diets. These acids, due to their high lipid 
solubility, diffuse into the non-glandular gastric cells causing acidification and damage to 
sodium transport, which leads to cellular injury and gastric ulceration. 
Current studies involve examination of fresh viable non-glandular tissue (most 
susceptible to gastric ulceration) from the stomach of horses. Tissues are placed in an 
Us sing chamber system, which allows measurement of tissue short-circuit current 
(sodium flow) and resistance across the tissue. A -decrease in short-circuit current and 
resistance are the first indicators of tissue damage, and precede gastric ulcer formation. 
These tissues then are viewed under the microscope after special staining to determine 
the nature and extent of cellular damage. 
Dr. Andrews' research suggests that low pH stomach acidity and volatile fatty acids, 
especially butyric, propionic and valeric acids, in contact with the stomach lining leads to 
cell damage. Also, valeric acid produced cell damage at a neutral pH. These cells lose 
their ability to transport sodium which leads to cellular swelling that, if exposure is long 
enough (6 hours) can lead to cell death and gastric ulceration. Examination of stomach 
tissues under light microscopy confirmed the presence of cell swelling in the non­
glandular squamous mucosa, the area most prone to gastric ulceration in horses. 
This research suggests that diets low in fermentable carbohydrates and high in protein 
and calcium (alfalfa hay) may be helpful in reducing stomach acid and VFAs aiding in 
the prevention of equine gastric ulcer disease. Also, diets could be developed to produce 
lower levels of these potentially harmful volatile fatty acids. In addition, the presence of 
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valeric acid in the stomach, since it causes damage at neutral pH, may be the reason why 
the gastric ulcers in some horses are resistant to treatment. 
Dr. David A Brian (coronavirus molecular hiologylpathogenesis) 
Fellows and Graduate Students: Dr. S. Senanayake, Dr. K. Nixon, Dr. A. Ozdarendelli, 
G.D. Williams, S. Raman, C. Gay, H. Wu. 
Dr. Brian's interest in basic molecular biology of viruses has resulted in discoveries of a 
fundamental nature for which his laboratory has received national and international 
recognition. His research focuses on coronaviruses which cause of some of the most 
costly respiratory and gastroenteric diseases of livestock and fowl, and disabling diseases 
of people. Efforts to control coronavirus infections have been frustrated by three major 
obstacles: 
1. An incomplete understanding of how coronaviruses replicate and persist in 
animals. 
2. The ability of coronaviruses to rapidly mutate into new pathogenic 
variants. 
3. The generally weak immune responses in animals to coronavirus 
vaccination and the logistical problem of inducing protective mucosal 
(local) immunity in the vulnerable newborn. 
The primary research focus in Dr. Brian's laboratory is the molecular biology of 
coronavirus replication. With funding from the USDA and the NIH, and modest support 
from the Center of Excellence, they are making an intense effort to understand how five 
separate genetic elements in the coronavirus function to regulate production of viral 
proteins and progeny virus. Research is being done also on a sixth genetic region, a hot 
spot for variability, in an effort to understand the determinants of this process. Genetic 
recombination (blending) at this site is a mandatory step used by the virus in the 
generation of messenger molecules that encode portions of the virus' genetic material. It 
is anticipated that information from these studies will significantly impact the design of 
new therapeutic strategies. 
Of special interest is how a newly discovered element at one end of the virus gene 
regulates replication of the genetic material. The element is a tRNA-like folded structure 
(a pseudoknot), that may regulate virus replication by incorporating a cellular protein in 
the virus replication machinery. Therapeutic interruption of such a virus-protein 
interaction may lead to a cure of virus infection. Interestingly, one candidate protein in 
this interaction is histidyl tRNA synthetase, a factor (auto antigen) in the human disease 
polymyositis. 
Dr. Brian's laboratory has also discovered a small genetic variant of the bovine 
coronavirus (a viral mini genome) that replicates in the presence of "normal" virus. This 
minigenome is being experimentally engineered to carry many kinds ofpotential antiviral 
molecules into cells. One molecule is an enzyme (a ribozyme) designed to destroy the 
gene on which the virus depends for replication (the polymerase gene). This novel 
therapeutic approach would, in theory, cure a virus-infected cell without killing it. 
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Dr. Alan G. Mathew (livestock enteric antibiotic resistance) 
Staff and graduate students: R. Clift, S. Chattin, D. Arnett, P. Cullen, P. Ebner, K. 
Garner, G. Pulliam, 1. Liu 
Antibiotics are commonly used in livestock and pets in the US. Therapeutic use of 
antibiotics continues to play a major role in combating disease organisms, while 
subtherapeutic use in feeds increases animal performance, decreases the numbers of 
infectious organisms in the environment, and lowers the prevalence of organisms causing 
foodborne illness in humans. 
In contrast to the above benefits, some evidence suggests that agricultUral use of 
antibiotics may be partly responsible for the emergence of drug-resistant bacteria, which 
in turn may decrease the efficacy of similar products used in human medicine. However, 
little information is available on strategies for controlling of antibiotic-resistant 
organisms. In particular, almost no information is available with respect to modern 
livestock production facilities, management, environmental conditions, or drug therapies 
that affect resistance in organisms. Because resistance may be transferred to bacteria 
from a variety of resistant bacteria and associated hosts, it is important that factors 
involved are characterized so that more effective control strategies can be formulated. 
A primary research focus of Dr. Mathew's group is to characterize genetic factors 
that lead to antibiotic resistance in animal and human pathogens. They also are 
investigating how different uses of antibiotics in livestock and pets affect antibiotic 
resistance patterns, concentrations, and shedding of food borne pathogens. They hope to 
determine the most effective antibiotic therapies and husbandry practices to maintain 
animal health, while at the same time limiting prevalence of food borne pathogens and 
antibiotic resistance of microorganisms. 
A recent accomplishment of his group has been the determination that resistance 
to a widely used antibiotic, apramycin is controlled by genes found on bacterial 
chromosomes, particularly in non-pathogenic E. coli found in the 01 tract of animals. 
Formerly, it had been assumed that such genes resided primarily on extrachromasomal 
plasmids which are highly mobile DNA elements frequently found in bacteria. This 
information indicates that resistance to apramycin is more persistent in some types of 
bacteria, and, thus, strategies for control will need to be revised. They have also 
developed a number of molecular techniques to quickly detect resistance genes and 
insertion points for those genes in bacterial genes and plasmids. This work has led to a 
more specific test for a particularly hazardous strain of Salmonella typhimurium, DTI04, 
which carries resistance for at least 5 antibiotics. The PCR-based test can easily and 
quickly differentiate between non-typhymurium salmonellae, S. typhimurium, and S. 
typhimurium DTI04 providing a powerful tool for epidemiological studies. 
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Other accomplishments of Dr. Matthew's group include the finding that various 
animal stressors, including heat and cold, increase the numbers of antibiotic resistant 
bacteria associated with livestock. In addition, investigations of the prevalence of 
resistant bacteria and food borne pathogens in pets are underway and have already 
provided important preliminary data that will ultimately lead to methods to reduce 
microbial risks associated with pets and companion animals. Additional work also 
continues to define sources and reservoirs of food borne pathogens in livestock units. 
Such information will be instrumental in the implementation of on-farm Hazard Analysis 
Critical Control Points (HACCP) strategies for control of specific food borne pathogens. 
Dr. Jack W. Oliver (bovine tall fescue toxicity) 
Co-investigators and staff: Dr. R. Linnabary, Dr. E. Schultze and Dr. B. Rohrbach, 
L.K. Abney, E.M. Bailey, M. Cottrell and J. Czarra 
Tall fescue toxicosis continues to be the primary grass-related disease in the 
United States in terms of economic loss to animal producers, affecting over 8.5 million 
beef cows and 700,000 horses. Tall fescue toxicosis is also a costly disease to Tennessee 
cattle producers, resulting in an approximate $100 million dollar annual loss due to 
unrealized production. Tall fescue is an attractive forage species because of its ability to 
withstand drought, poor soil conditions and intensive defoliation from grazing. It is 
grown on more than 34 million acres of pasture, but 75% of the pastures are infected with 
the endophytic-fungus, Neotyphodium coenophialum, at a sixty percent or greater level. 
Most of the infested pastures are in the Southeastern United States. 
The endophyte-grass association results in the production of alkaloid toxins 
produced by the fungus or by the plant in response to the fungus. The alkaloids are 
biologically active causing a decrease in appetite and impaired reproduction and growth 
in animals. Endophyte-infected tall fescue has greater forage and seed productivity than 
the non-infected variety and is more drought tolerant. At the same time, tall fescue 
toxicosis is a costly disease to animal producers, causing severe reductions in weight 
gains, milk production and fertility. 
Results of studies by Dr. Oliver's group have established that vascular damage is 
a central event that occurs when herbivores consume infected tall fescue . As a 
consequence of injury to blood vessels, blood flow to tissues is impaired causing 
localized tissue damage and thereby affecting the function of body systems. The 
abnormalities in blood flow are integrally related to the economic losses encountered by 
the cattle industry in the United States. Dr. Oliver has been examining toxicity associated 
with purified alkaloids that are suspected of being the primary tall fescue toxins (i.e. 
ergine, ergovaline). The long range goal of these studies is to understand how the 
individual toxic alkaloids cause damage to tissues of cattle because little is known 
regarding which of the alkaloids in tall fescue cause(s) the lesions in this syndrome. 
Studies have been completed on analyses of various parameters of blood and 
tissues in steers that grazed endophyte-infected tall fescue over a three-year period. 
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Markedly suppressed levels of serum copper were recorded in consecutive years, and 
copper deficiency may be the basis of the poor haircoats in these cattle. Gamma globulin 
(antibody) levels these cattle also were significantly reduced, suggesting that 
immunosuppression is an important aspect of the disease too. This infonnation of tall 
fescue toxicity in cattle will be important in evaluating anti-fescue toxicosis treatments. 
Continued research will be focused on the chronic effects of the two important 
alkaloids of toxic tall fescue, ergine and ergovaline. Cattle will be treated with each of 
these alkaloids to evaluate their effect on the function of a specific blood vessel receptor 
(alpha-2 adrenergic). Dr. Oliver detennined that ergovaline administration at the rate of 
0.2 uglkglhour caused the typical decrease in the hormone (prolactin) in blood that occurs 
in cattle grazing on fungus-infected tall fescue pastures. Since the lining cells of blood 
vessels (endothelial cells) are damaged by exposure to the alkaloids, several 
inflammatory mediators associated with endothelial cell injury will be measured in the 
serum of the cattle that are infused with ergine or ergovaline. 
Laboratory studies with isolated bovine endothelial cells or smooth muscle cells, 
grown in culture were treated with various concentrations of ergovaline and ergine. Both 
of these alkaloids are toxic to endothelial cells but ergovaline was considerably more 
potent. Dr. Oliver's results indicat~ that manipulation of the infection allowing ergine 
production in the plant but elimination of ergovaline presence would be beneficial. The 
ergine is necessary to convey insect resistance to tall fescue and the toxic effect would be 
minimized because the absence of ergovaline. Reducing the toxic effect of ergovaline in 
cattle will allow increased use of tall fescue, a forage with excellent nutrient quality, and 
root development that helps to control soil erosion. Dr. Oliver's research has been 
supported by the Center of Excellence, but his primary support is from the USDA's 
National Research Initiative. 
Dr. Stephen P. Oliver (bovine mastitis) 
Fellows and Staff: R. Almeida, W. Fang, B. Gillespie, M. Lewis, D. Luther, S. Ivey, L. 
Coleman. 
Research conducted by Dr. Oliver focuses on mastitis in dairy cows caused by 
environmental organisms. Several kinds of bacteria are capable of infecting the udder 
causing mastitis. These pathogens invade the udder, mUltiply there and produce harmful 
substances that result in inflammation, reduced milk production and altered milk quality. 
Control of mastitis is extremely difficult because of the many types and sources of mastitis 
pathogens that can cause the disease. The National Mastitis Council estimates that mastitis 
costs U.S. dairy producers over two billion dollars annually. In Tennessee, losses due to 
mastitis may exceed $25 million annually. Thus, mastitis in dairy cows is likely the most 
costly disease affecting dairy producers in Tennessee, the U.S., and throughout the world. 
Dr. Oliver was the first to show that mastitis in pregnant dairy heifers occurred 
frequently near calving and that many of these infections persisted into early lactation. His 
research has resulted in a simple, effective and inexpensive method for controlling mastitis 
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in heifers. Intra-mammary antibiotic infusion before calving, was shown to be an 
effective procedure for: 
1) eliminating many infections in heifers during late gestation 
2) reducing the prevalence of mastitis in heifers during early lactation 
3) for reducing the prevalence of mastitis in heifers throughout lactation. 
He documented that a return of $12-$20 for each dollar spent was possible using this 
approach. 
Several studies over the past 13 years at the UT Dairy Experiment Station involved 
collection of almost 200,000 milk samples for microbiological evaluation at intervals before 
calving, during lactation and during the dry period. Data from those studies have been 
computerized and this mastitis database may be the largest in the world. It now is being 
exploited for retrospective studies and will provide valuable information on the spread of 
mastitis pathogens, such as Streptococcus uberis and Streptococcus dysgalactiae, in high­
producing dairy herds. Recently, they evaluated the influence of mastitis on reproduction in 
Jersey cows and found it profoundly impairs reproduction during early lactation. 
Dr. Oliver has been actively seeking the identification of virulence (severity) factors 
produced by certain mastitis organisms (Streptococcus species) and implications of 
immunity to them. In many dairy herds Streptococcus uberis and Streptococcus 
dysgalactiae are responsible for a high proportion of mastitis with varying degrees of 
severity in lactating and non-lactating dairy cows. Strategies for controlling these mastitis 
pathogens are poorly defmed and inadequate. This research focuses on: 
1) genetic characterization of Streptococcus uberis and Streptococcus dysgalactiae 
2) characterization of Streptococcus uberis and Streptococcus dysgalactiae with 
particular emphasis on factors involved in adherence and invasion into 
mammary epithelial cells 
3) evaluation of immunity after immunization of dairy cows with components of 
Streptococcus uberis and Streptococcus dysgalactiae 
4) effectiveness of experimental vaccines to Streptococcus uberis and Streptococcus 
dysgalactiae mastitis during the nonlactating period 
Dr. Oliver's research group has determined that Streptococcus uberis and 
Streptococcus dysgalactiae readily adhered to and invaded cells lining the bovine udder. 
Chronic infections then may develop, and their intracellular location may protect these 
bacteria from anti-microbial drugs and host defense mechanisms. Mastitis pathogens 
cultured in the presence of mammary epithelial (lining) cells in the laboratory synthesize 
proteins not detected when bacteria are cultured alone. These unique proteins likely are 
involved in virulence of bacteria, including their capacity to adhere and invade mammary 
epithelial cells. Thus, culture of mastitis pathogens in the laboratory in the presence of 
mammary epithelial cells may result in expression of bacterial virulence factors similar to 
that which occurs in the animal. This important discovery will be exploited for the 
development ofvaccines and management ofmastitis. 
Dr. Oliver's expertise in mastitis and milk quality has led also to a new research 
initiative in food safety. The primary goal is to provide comprehensive information on the 
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occurrence and distribution of Salmonella, Escherichia coli 015 7:H7, and Campylobacter 
jejuni in bulk tank milk, feces of cull dairy cows and the environment in dairies. Antibiotic 
resistance patterns and molecular characterization of foodborne pathogens is also being 
done. 
Dr. Oliver has increased the awareness of scientists, extension specialists, dairy 
producers and pharmaceutical companies of the importance of environmental pathogens in 
bovine mastitis. Furthermore, he has discovered fundamentally important information that is 
critical for controlling the heterogeneous organisms that cause mastitis. Dr. Oliver's 
research philosophy is to design and conduct innovative and useful studies and to report to a 
wide variety of constituents. The ultimate goal of this research is to enable dairy producers 
in Tennessee, the U.S., and throughout the world to enhance the quantity and quality of milk 
produced and thus reduce the economic impact ofmastitis. 
Dr. Oliver's research has been supported for several years by the Center of 
Excellence, but his primary funding has been derived from substantial grants from 
foundations, FDA and the pharmaceutical industry. 
Dr. James D. Godkin (reproduction) 
Fellows, Staff and Graduate Students: Dr. D. Eberhardt, T. Livingston, H. King, S. 
MacKenzie, M. Roberts 
The focus of Dr. Godkin's research group over the past few years has been the 
study ofproteins that communicate fetal-maternal interactions and result in the successful 
maintenance of pregnancy. One important discovery was that interferon-tau, a placental 
protein, interacts with the uterus and alters maternal hormonal balance and maintains 
early pregnancy in ruminants such as cattle, sheep, goats, and buffalo. Another focus of 
Dr. Godkin's laboratory is reproductive efficiency with respect to the effect of growth 
factors and certain vitamin A-like proteins (retinoid-associated) and their genes on the 
early embryo, ovary, oviduct and uterus. 
The major current focus of Dr. Godkin's laboratory is on factors that control 
development of the early embryo of domestic livestock. Recently, they made the 
remarkable discovery that treatment of animals with vitamin A-like compounds 
(retinoids), just prior to ovulation, results in improved viability of embryos that then 
develop following fertilization. In addition, his laboratory studies indicated that 
treatment of embryos with retinoids dramatically improved embryonic development. The 
goals of this research are to improve reproductive efficiency through the use of retinoid 
administration procedures, to develop more efficient assisted reproductive procedures and 
to determine the mechanisms by which retinoids affect oocyte (egg) maturation, 
embryonic development and survival. 
This research has the potential to improve reproductive efficiency in livestock and 
improve assisted reproductive procedures in humans. It also has an application for the 
preservation of endangered species. 
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A patent application has been filed covering the use of retinoids in assisted 
reproductive procedures with the assistance of the UT Research Corporation. Dr. 
Godkin's research has received support from the Center of Excellence which has been 
leveraged into substantial funding from the USDA's National Research Initiative. 
Animal and Laboratory Models of Disease 
Dr. Michael McEntee (cancer modeling) 
Collaborators, Staff and Graduate Students: Dr. 1. Whelan, A. Cruikshank, N . Neilsen 
Dr. McEntee' s research focuses on defining the relationship between tissue levels 
of polyunsaturated fatty acids, their metabolism as bioactive lipids (such as prostaglandin 
E2), and forms of cancer to which they have been linked. In collaboration with a 
biochemist in the Department of Nutrition at UT, Dr. J. Whelan, he demonstrated 
recently that specific dietary polyunsaturated fatty acids can significantly protect against 
the development of intestinal cancer in a mouse model of the human disease. Non­
steroidal anti-inflammatory drugs like aspirin inhibit the metabolism of polyunsaturated 
fatty acids into various prostaglandins. Their research involved the simultaneous 
pharmacologic and dietary manipulation of tissue polyunsaturated fatty acids 
concentrations. 
Polyunsaturated fatty acids derived from fish oils reduced the incidence of this 
form of neoplasia by 50% in comparison to polyunsaturated fatty acids common in the 
U.S. diet (i.e. animal fat and vegetable oil). Their research suggested that this protective 
effect was specifically attributed to longer chain, highly unsaturated polyunsaturated fatty 
acids. Dr. McEntee also demonstrated for the first time in an animal that prostaglandins 
produced from the "bad" tissue polyunsaturated fatty acids specifically contributes to 
intestinal tumor growth. Inhibition of the metabolism of polyunsaturated fatty acids 
found in com oil and red meat to prostaglandins significantly contributes to intestinal 
. .
carcmogeneSlS. 
The importance of prostaglandins in production of tumors was subsequently 
confirmed in experiments where tumors were eliminated following treatment with an 
antibody that specifically inactivates this polyunsaturated fatty acid product. 
Prostaglandin E2 acts through specific cell receptors and they have shown that it is 
produced by the non-neoplastic part of intestinal tumors of their mouse model (as it is in 
humans). They are currently attempting to characterize the distribution of the 
prostaglandin E2 receptors in these lesions in order to better understand the link between 
the production/target activity of this specific bioactive lipid and intestinal carcinogenesis. 
Recent data suggest that the molecular changes contributing to intestinal carcinogenesis 
in humans and their mouse model also occur in pet dogs that develop this form of 
neoplasia. This strongly implies that the beneficial effects of dietary and pharmacologic 
intervention demonstrated in the mouse model would directly translate to dogs, as well as 
humans. 
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In addition to the above experiments, studies have been initiated to investigate the 
contribution of polyunsaturated fatty acids and their metabolites to another common form 
of neoplasia that has been strongly linked to dietary fats in humans, prostatic cancer. 
Dr. McEntee receives support from the Center of Excellence, but his primary 
funding is derived from the Department of Defense, American Institute of Cancer 
Research and Monsanto. 
Dr. Barry T. Rouse (herpesvirus immunity and pathogenesis) 
Fellows, Staff and Graduate Students: S. Chun, S. Deshpande, S. Kug Eo, U. 
Kumaraguru, S. Lee, T. Sobhani, M. Zheng 
Dr. Rouse's research deals with the recognition and interaction of the body with 
viral infections. This group has studied herpes simplex virus, an agent that affects the 
majority of humans. The virus persists indefinitely in infected individuals, and some 
suffer periodic lesions which are painful and inconvenient. When such lesions occur in 
the eye, they can lead to blindness. Dr. Rouse's laboratory is involved in studies directed 
to understand the mechanisms by which herpes simplex infection causes blindness. 
Dr. Rouse's approach to understanding the interaction between herpes simplex 
virus and the immune system is to exploit model infections such as the mouse system as 
an animal model. Their aim is to understand how cells and molecular events set into play 
by herpes simplex virus lead to chronic inflammatory lesions or to resolution of disease. 
Ultimately, it may prove possible to manipUlate the host defenses either to achieve 
protection by vaccines or resolution of injury by substances introduced by gene transfer 
technology and capable of influencing the immune response. 
In the last year they have used mouse models which have been genetically 
manipulated to cause deficient immune systems and thereby to evaluate whether the 
ocular lesions are the consequence of an autoinflammatory (self-destructive) reaction. 
Their results do not support the latter hypothesis. Instead the evidence indicates that 
herpes simplex replication in the eye causes the output of molecules called cytokines and 
chemokines which activate certain invading cells of the immune system (T lymphocytes) 
to release inflammatory substances. This mechanism is referred to as bystander 
activation. Such a mechanism could represent an important component of any chronic 
inflammatory reaction. 
The other major activity in Dr. Rouse's laboratory is to understand the cell and 
molecular events that occur during an immune response to novel DNA vaccines. They 
have identified that a process called "cross priming" is the main event in this process and 
that it is mediated by a "chaperone molecule" bound to a protein (peptide). They are 
exploring the use of chaperone-bound peptides as a unique means of vaccination. This 
could have a major impact in the prevention of viral diseases in people and animals. 
In studies of herpetic ocular disease, Dr. Rouse's group has found that 
neovascularization is an essential event in the pathogenesis of this disease. Moreover, 
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they have determined that HSV -induced VEGF is involved in this process and that 
intentional diminution of the angiogenic factors production limits the severity of the 
viral-induced corneal lesions. Their data document for the first time the essential role of 
angiogenesis in the pathogenesis of herpetic stromal keratitis and also indicate that the 
therapy of this disease could benefit by procedures which diminish angiogenesis. 
The Center of Excellence supports some aspects of this research which is funded 
primarily by substantial grants from the National Institutes of Health. Their work has 
generated national and international interest, and the laboratory is recognized as one of 
the premier viral immunology programs in the country. Dr. Rouse is one of a very select 
group of investigators in this country holding three RO 1 NIH awards simultaneously. 
Dr. Hildegard M. Schuller (experimental oncology) 
Fellows, Staff and Graduate Students: Dr. H. K. Plummer III, Dr. Brian A. Jull, Dr. Y. 
Cakir, N. Neilsen, and K. Walker 
Lung cancer is the leading cause of cancer deaths in all industrialized countries. 
East Tennessee has one of the highest lung cancer rates in the United States. Although 
cancers at other organ sites are more than twice as common, their cure rate is 
considerably higher. The most common cancer in men is prostate cancer, with a cure rate 
of 84%. Breast cancer is the leading type of cancer in women with a cure rate of74%. In 
contrast, 158,700 (89.3%) of the 177,700 patients diagnosed with lung cancer in the year 
1997 died within 12 months of diagnosis. 
Smoking and exposure to second-hand smoke are the most intensively studied and 
best-documented risk factors for the development of lung cancer. Contrary to cancers at 
other organ sites, the incidence of lung cancer continues to rise in all industrialized 
nations. Moreover, teen smoking in the U.S. has increased at an alarming rate, thus 
setting the stage for even higher numbers of lung cancer cases 30-40 years from now. 
Another important contributing factor to the rise in lung cancer cases is the growing 
number of lung cancers developing in individuals never exposed to primary or second­
hand smoke. This trend, which has been globally observed during the last two decades in 
all industrialized countries, is particularly evident for pulmonary adenocarcinoma. Of the 
six types of lung cancer recognized by the World Health Organization classification, two 
(small-cell carcinoma and adenocarcinoma) accounts for 90% of all lung cancers, but 
30% of these cases do not have a history of exposure to primary or second hand smoke. 
The lung cancer "epidemic" is closely related to a globally observed rise in 
chronic lung diseases such as bronchitis, bronchiolitis, asthma, emphysema, and chronic 
obstructive pulmonary disease. This disease complex, which is often referred to as 
"allergies" has the same geographic distribution as lung cancer with which it shares some 
risk factors such as smoking and air pollution. Accordingly, East Tennessee, which has 
one of the highest lung cancer rates in the U.S., is also often referred to as "the land of 
allergies." For all lung cancer types, chronic lung disease has been identified as a risk 
factor even without a history of exposure to smoke. 
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Dr. Schuller's research has been dedicated to the study of lung cancer for over 20 
years. It is her belief that effective strategies for the prevention and therapy of this 
disease complex can only be based on an in-depth understanding of the regulatory 
mechanisms which govern the growth of normal lung cells and the cancers arising from 
such cells. In contrast to other laboratories that are searching for the "magic molecular 
event" responsible for the genesis of all lung cancers, she hypothesized that different lung 
cell types and different types of lung cancer may be governed by different regulatory 
mechanisms, which in tum may be affected differently by known risk factors for the 
disease. 
Dr. Schuller's achievements in lung cancer research have been recognized 
nationally and internationally. Her research has been supported by the Center of 
Excellence, but her primary support comes from substantial grants of the National Cancer 
Institute and the pharmaceutical industry. 
Dr. Schuller's group previously determined that the growth of small cell lung 
carcinoma and the cell of origin of this cancer type (pulmonary neuroendocrine cell) is 
regulated by a specific cell surface receptor (nicotinic acetylcholine) which has an 
important biochemical function (calcium channel). She found also that the tobacco­
specific carcinogenic product (NNK) activates this receptor with high affinity. Binding 
of this product to the receptor causes a release of a biochemically active substance 
(serotonin) by these cells and that this substance markedly stimulates cell division when 
it is taken up by other cells. This is an important finding because it links, for the first 
time, the stimulation of a specific receptor by a tobacco-specific toxicant resulting in the 
activation of a series of cell-specific events that may result in uncontrolled growth. 
Experiments are now underway to test the hypothesis that substances which inhibit the 
re-uptake of serotonin will protect against the development and spread of small cell lung 
carcinoma. These drugs are already approved for the treatment of psychiatric diseases 
and migraine and could immediately enter clinical trials in smokers and small cell 
carcinoma patients. 
Laboratory studies with various cultures of small cell lung cancer cells and 
pulmonary neuroendocrine cells suggest that smoking or chronic exposure to the product 
NNK, increases the concentration of the target receptors on these cells. Dr. Schuller now 
is working with Dr. Kabalka of the Department of Chemistry on the development of 
novel cancer imaging agents which selectively bind with high affinity to this receptor that 
will allow for a selective and highly sensitive detection of small cell carcinomas in people 
(by positron emission tomography). This will constitute an important clinical application 
ofher research. 
Dr. Terry W. Schultz (toxicity modeling) 
Staff and Graduate Students: G. Sinks, B. Gregory, J. Seward, and E. Hamblen 
Research in the Biological Activity Testing and Modeling Laboratory focuses on 
the development of databases for structure-toxicity modeling and the development and 
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validation of such models. The values of structure-toxicity models lie in their ability to 
predict toxic potency from molecular structure. This means that hazard assessment can 
be conducted while conserving time, manpower, resources, and animals. 
Toxic potency is related to the uptake of the toxicant from the environment and its 
interaction with certain molecular sites of action. Since certain properties (such as 
hydrophobic, electronic, and steric factors) are related to molecular structure, Dr. 
Schultz's group focuses on identifying global descriptors of such properties that are best 
in modeling ofuptake and interaction. Previous work by Dr. Schultz's group have shown 
that the site of action for toxic events is the cell membrane. In the case of covalent 
events, it is soft nucleophiles associated with membrane-bound proteins, whereas, in the 
case of non-covalent events it is the fatty acids of the membrane lipid bilayer. 
The Biological Activity Testing and Modeling continues to make excellent 
progress in the development of a better understanding of chemicals that mimic estrogens. 
They have, with help from the Center, developed one of the largest single-endpoint 
databases for xenoestrogens in the world. From these data, Dr. Schultz and his 
collaborators have developed a series of molecular structural indicators that allow for the 
rapid screening of large sets of industrial chemicals for those that have the potential to 
cause endocrine disruption. 
Work also continues on standardizing the Saccharomyces cerevisiae-based lac-Z 
reporter assay as an in vitro assay, which allows for the quantitative assessment of 
chemicals that alter estrogen receptor-mediated transcriptional activity. The estrogenic 
activities of 17-B-estradiol, biphenyl, chlorinated biphenyls (CB) and Aroclor mixtures 
have been examined. Results suggest that the use of plastic microtiter plates in toxicity 
testing with strongly hydrophobic chemicals may result in an underestimation of toxicity. 
Using the modified yeast estrogen assay, full agonist activity was observed for 4-CB, 
2,4,6-CB, and 2,5-CB, while each of the Aroclor mixtures were only partial agonists. 
The equivalent ECso values in ppm were in environmentally relevant concentrations of 
biphenyl (19 ppm), 4-CB (4.5 ppm), 2,5-CB (21 ppm), 2,4,6-CB (0.8 ppm), Aroclor 1221 
(2.9 ppm), Aroclor 1242 (0.65 ppm), and Aroclor 1248 (2.3 ppm). 
Other recent achievements by this group include improvement in descriptor 
selection for the prediction of toxic potencies of electrophiles. Specifically, Quantitative 
Structure-Activity Relationships (QSARs) relating toxic potency with hydrophobicity 
quantified by the l-octanollwater partition coefficient and electrophilic reactivity 
quantified by the molecular orbital parameters, either the energy of the lowest occupied 
molecular orbital or maximum acceptor superdelocalizability reveals maximum acceptor 
superdelocalizability to be the better electrophilic parameter for modeling of industrial 
aromatic chemicals. 
Patricia K. Tithof(cardiovascular physiology and toxicity) 
Collaborators, Staff and Graduate students: Dr. M. Peters-Golden, Dr. H. Schuller, Dr. 
H.C. Wang, Dr. R. Donnell, M. Elgayyar, M.A. Barnhill 
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Dr. Tithors research program in cardiovascular physiology concerns the effects 
of specific components of cigarette smoke on the biology of blood vessel lining 
(endothelial) cells and metabolism of a potent physiological chemical messenger, 
arachidonic acid. The latter is a fatty acid that is present in high quantities in the 
membranes of all cells and is a substrate for the production of eicosanoids, a family of 
biologically active lipid mediators. The latter have an important role in several diseases 
including asthma, arthritis, cancer and atherosclerosis. 
Smoking, which greatly augments the process of atherosclerosis, increases the 
risk for heart attack or stroke by as much as 50%. Recent epidemiologic studies indicate 
that a high fish diet or frequent use of aspirin significantly decreases mortality rates due 
to heart attacks in heavy smokers. Fish contains high levels of certain fatty acids, which 
decrease the availability of arachidonic acid and also inhibit the production of 
arachidonic acid-derived eicosanoids. The protective effects of these fatty acids and 
aspirin against smoking-induced atherosclerosis suggest that components of cigarette 
smoke stimulate the arachidonic acid pathway. However, no previous studies have 
focused on the specific components of cigarette smoke responsible for this effect. 
Several compounds are contained in high concentration within the tar fraction of cigarette 
smoke. These include methylanthracenes (1,500 ng/cigarette), phenanthrene (362 
ng/cigarette) and benzo(a)pyrene (25 ng/cigarette). Benzo(a)pyrene accelerates the 
development of atherosclerosis in animal models. 
Endothelial cells form a single cell layer lining the blood vessel wall. Endothelial 
cell death and loss is a critical and important event in the early development of 
atherosclerosis. Loss of the endothelial cell layer results in inflammation of the vessel 
wall, vasoconstriction and clot formation; events important in the development of heart 
attacks and strokes. Previous studies indicate that cigarette smoking increases the rate of 
endothelial cell loss; however, neither the mechanism of cell death nor the specific 
components of cigarette smoke responsible have been elucidated. 
These studies indicate that exposure of porcine aortic endothelial cells or human 
coronary artery endothelial cells to these compounds in cigarette smoke causes release of 
arachidonic acid. Furthermore, this release of arachidonic acid is associated with loss of 
endothelial cell viability through stimulation of a process known as apoptosis or 
programmed cell death. Apoptosis induced by these compounds can be inhibited by the 
fatty acid, eicosapentaenoic acid, which exists at high concentrations in fish. These 
results suggest that methylanthracenes, phenanthrene and benzo(a)pyrene may be 
important components of cigarette smoke that augment atherosclerosis through a process 
that involves arachidonic acid-mediated killing of endothelial cells. 
Dr. Tithof also has initiated studies to investigate the effects of derivatives of 
nicotine on endothelial cell function. A derivative of nicotine, NNK, plays an important 
role in smoking-induced lung cancer. Recent studies in collaboration with Dr. Hildegard 
Schuller suggest that NNK induces tumor formation by a mechanism that involves 
release of arachidonic acid by stimulation of certain cell receptors (beta-adrenergic). The 
finding that NNK binds to beta-adrenergic receptors has important implications 
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concerning a potential effect of NNK on the cardiovascular system. Evidence indicates a 
role for the beta-adrenergic system in the cause of atherosclerosis because beta­
adrenergic blocking agents prevent endothelial cell injury Beta-adrenergic blockade also 
reduces endothelial cell injury induced by cigarette smoke. 
The effects ofNNK on endothelial cell viability were investigated by Dr. Tithors 
group. NNK, at very low concentrations (100 nM) caused apoptotic cell death of 
endothelial cells. Their results suggest that it was the result of NNK binding to beta­
adrenergic receptors and that the arachidonic acid cascade was involved. 
These studies provide novel findings concerning the effects of specific 
components of cigarette smoke on endothelial cell function and suggest a novel 
mechanism by which cigarette smoke augments atherosclerosis. These studies may 
contribute to the development of effective measures for preventing cardiovascular 
complications in smokers. Moreover, identifying specific components of cigarette smoke 
that augment disease may lead to the development of safer cigarettes. These strategies 
may be particularly important because the incidence of smoking continues to rise, despite 
intensive efforts to educate people about the hazards of smoking. 
Dr. Hwa-Chain R. Wang (molecular oncology) 
Fellows: K. Fecteau, 1. Mei, Y. Sun, M. Tan 
Dr. Wang's long-term research goals concerns tumor-specific intracellular 
molecular signaling networks and to uncover signaling pathways that can be induced by 
anticancer agents to lead cancerous cells into programmed cell death (apoptosis) or 
growth arrest ( cell quiescence). 
Short-term goals are to identify intracellular signaling elements whose activation 
is involved in induction of apoptosis or growth inhibition of cancer cells. A corollary to 
this is to identify novel anticancer agents, which may selectively induce apoptosis of 
cancer cells while sparing normal cells. Ultimately, he expects to apply the 
understanding of intracellular signaling control to anticancer therapeutics and prevention. 
Currently, Dr. Wang focuses on three projects. The first is to understand the 
molecular and cellular function of a family of novel intracellular enzymes (Krs and QIK), 
which are induced in resting cells and cells undergoing programmed cell death. The 
second is to study molecular and biological activities of a novel natural anticancer agent 
(FR90 1228), which selectively induces programmed cell death of cancer cells. The third 
is to study changes in molecular and biological properties of human breast cells during 
development into cancerous stages induced by tobacco-related carcinogens. 
Dr. Wang has identified a family of novel enzymes (kinases: SAMKJKrs1 and 
QIK) that are activated in normal resting cells, in quiescent cells, or in cancerous cells 
undergoing programmed cell death as a result of a variety of physiological, chemical or 
physical stresses. QIK is an active form of gene products of the Krs 1 gene. Induction of 
QIK activity is involved in establishing cell quiescence but additional activation may 
result in cell death. He is investigating the molecular and biological roles of these 
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enzymes in cancer development and programmed cell death. Uncovering the apparent 
novel signaling pathway that cross-links cancer development of cells to programmed cell 
death should be directly exploitable for development of anticancer therapeutics. 
Investigation into the molecular mechanisms of potential anticancer therapeutic 
agents on a variety of cancer cell types particularly human breast cancer cells is ongoing. 
Cancerous mouse embryo cell cultures and various human tumor cell cultures are used to 
screen anticancer agents. Studies on the molecular effects of a novel natural anticancer 
agent FR901228 on different intracellular metabolic signaling pathways should uncover 
the mechanism of this agent to selectively induce programmed cell death in cancerous 
cells. Dr. Wang determined that at least five important intracellular metabolic signaling 
pathways including the QIK pathway are affected. The information will be a basis for 
clinical trials using FR901228 in combination with other anticancer agents. 
To mimic long term exposure of cells to the tobacco-specific carcinogen NNK, 
cultured human breast epithelial MCFI0A cells were treated with low doses of NNK 
repeatedly. Cell clones which acquired tumor properties were isolated and subjected to 
studies of alterations in signaling pathways and cell growth. This is a pilot project to 
establish biochemical evidence of tobacco-specific carcinogens in the induction of 
human breast cancers. 
Dr. Wang's research is supported by the Center of Excellence, but his primary 
funding source is the National Institutes of Health (National Cancer Institute and National 
Institute of Dental Research). 
Dr. Xuemin Xu (molecular basis ofneurodegenerative disease) 
Staff and Graduate students: G. Mao, Ph.D., Y. Shi, W. Gao, and E. Laag 
The long-term goal of Dr. Xu's research is to understand the molecular and cellular 
mechanism of Alzheimer's disease, and the formation of senile plaques, the pathological 
hallmark of this disease. His group is conducting two projects. One is to determine the 
pathological function of a substance (presenilin 1) in brain degeneration and the genesis of another 
substance (amyloid) observed in Alzheimer's disease. The other project is to determine the role of a 
certain protein (apolipoprotein E) in the formation and clearance of another protein involved 
Alzheimer's disease CI3-amyloid peptide). 
Alzheimer's disease is a progressive degenerative disorder, characterized by memory loss, 
confusion, and a variety of cognitive disabilities. An estimated four million American suffer from 
Alzheimer's disease. It is the fourth major cause of death in the United States following heart 
disease, cancer, and stroke. Alzheimer's disease is the third most costly disease in the U.S. With 
the rapid growth of the senior population, Alzheimer's disease poses, besides its tragic personal 
impact, serious problems to families, caregivers, government and health care in institutions. 
Molecular genetic analysis of familial (heritable) Alzheimer's disease has led to the 
identification of three Alzheimer's disease-causative genes, those of l3-amyloid precursor protein, 
presenilin 1, and presenilin-2. A fourth gene encoding apolipoprotein E has also been associated 
with Alzheimer's disease as a risk factor but not as a causative gene for Alzheimer's disease. 
22 

Among these Alzheimer's disease -causative genes, mutations in presenilin 1 gene account for the 
majority of the known cases of familial Alzheimer's disease. Presenilin 1 has been implicated in 
two pathological events: (1) the generation of amyloid-~ peptide, which is the building block of the 
toxic "plaques" characteristic of brain tissue from patients with Alzheimer's disease, and (2) 
programmed cell death, or apoptosis, a natural process in which unneeded or worn-out cells 
commit suicide. However, questions regarding the mechanisms by which the mutations in 
presenilin 1 proteins alter ~-amyloid precursor protein processing and cause programmed cell 
death, as well as the normal function of presenilin 1, remain to be answered, which is the goal of 
their current research project. 
Recent work resulted in the identification of a novel molecule (PSAP) which is capable of 
inducing programmed cell death, one of the mechanisms of neuronal cell death observed in 
Alzheimer's disease brains. It reacts specifically with presenelin 1. This finding established for the 
first time the molecular link between presenelin 1 and programmed cell death. Currently, we are 
conducting the experiments to determine the role presenelin 1 has in regulating PSAP-induced 
programmed cell death and with other Alzheimer's disease protein structures such as amyloid 
plaques and neurofibrillary tangles. This study will contribute to understanding the pathological 
function of presenilin 1 and will provide new insight into the mechanism of Alzheimer's disease. 
This study may also lead to the identification a new therapeutic target of Alzheimer's disease 
treatments. 
Dr. Xu's studies in exploring the role of apolipoprotein E in ~ amyloid peptide formation 
suggests that these substances bind together to form complexes that interfere with the function of 
a critical enzyme a-secretase. The binding of apolipoprotein E to newly generated ~ amyloid 
peptide also may play a role in determining whether the latter is deposited or cleared. These 
studies will lead to a better understanding of the mechanism by which the apolipoprotein E is 
involved in Alzheimer's disease. 
Dr. Xu's experiments are conducted with laboratory models, including brain 
(glial) cells containing the genes of apolipoprotein E and for amyloid precursur protein 
and in a yeast two-hybrid system. Because mutations in the presenilin 1 gene are 
associated with the majority of familial Alzheimer's disease, these studies may provide 
important information for the early diagnosis and therapy of this disease. 
Dr. Xu's work is funded by grants from the National Institutes of Health, Sigma 
Kappa and by the Alzheimer's Association. He receives support also from the Center of 
Excellence. 
Dissemination of Research to the General Public 
Dr. Nancy Howell 
One important function of the Center of Excellence is to provide information to 
the general public. This information may increase the public's awareness of research and 
may provide individuals with valuable results that may improve their lives or their 
agribusiness. 
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To distribute information the College of Veterinary Medicine uses several 
methods. A general newsletter is distributed twice a year throughout Tennessee and 
beyond, highlighting research activities. Features concerning on-going research, in 
addition to results from concluded research projects, are included in the publication, 
Veterinary News, which is written for general audiences. Features also appear in other 
University of Tennessee publications, including UT Agriculture, UT Alumnus and 
Tennessee AgriScience. 
In addition, news releases are distributed to state media and to regional and 
national media. Television and print publications produce numerous features about the 
College each year, many related directly to research conducted through the Center of 
Excellence. Public displays about the College frequently include highlights of COE 
research. Center of Excellence researchers are invited to share their research not only 
professionally, but as speakers to commodity groups, civic groups and other interested 
individuals. 
Research is a component of the College's web site, including COE projects such 
as the tall fescue toxicity research and other research projects. 
Dissemination of research results through the news media helps inform the public 
and provides citizens with a better understanding of the practical applications of science 
in their daily lives. 
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FUTURE PLANS 

Much of the Center's efforts during the present year (2001-2002) and next will 
concentrate on promoting the development of newly recruited investigators and in the 
promotion of initiatives to enhance the research capacity and direction of the Center. 
This year the Center is expending $322,500 to fund 13 projects proposed by investigators 
in the College of Veterinary Medicine and in the College of Agriculture and Natural 
Resources. In addition equipment grants totaling approximately $150,000 have been 
approved. Objectives for the two years are listed and explained as follows: 
• 	 The Center will actively seek areas for enhanced research possibilities to support 
its objectives. As an example, in December 2001 the Center sponsored a 
"brainstorming" session attended by representatives of the clinical departments of 
the College of Veterinary Medicine, biomedical engineering and material science 
faculty of UT's College of Engineering, and administrators from ORNL's 
Materials and Ceramics Division. Focus groups were formed to continue the 
interactions with the intent to determine areas for collaborative efforts. Plans 
include inviting a representative from the newly created National Institute of 
Biomedical Imaging and Biomedical Engineering to discuss areas of funding 
interest. Additional plans include a planning session with a DARPA official to 
explore funding opportunities in the bioterrorism arena. 
• 	 The Center will explore possibilities to interact cooperatively with other UT 
centers to promote joint research interests. As an example, the previously 
mentioned biomedical engineering focus groups involve faculty in the THEC 
Center for Materials Processing and Center for Environmental Biotechnology. In 
addition, the Center is currently supporting a project jointly funded with the Food 
Safety Center. 
• 	 The Center will participate conceptually and materially in strategic planning to 
develop areas of investigative strength in the College of Veterinary Medicine and 
the UTIA. 
• 	 The Center will increase its involvement in research training of veterinary 
students and graduate students through the introduction of matching travel grants 
and the increased use of stipend upgrades to help in the recruitment and retention 
of top quality graduate students. 
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TABLE 1 

CENTER OF EXCELLENCE IN LIVESTOCK DISEASES 

AND HUMAN HEALTH BENCHMARKS OF FACULTY ACCOMPLISHMENTS 

2000 
Actual Average 
Number of: 
Articles 45 (2.8) 
Books or Book Chapters 2 (0.12) 
Published Proceedings 27 (1.7) 
Total Publications 74 (4.6) 
Abstracts 14 (0.9) 
Invited Participation at: 
Regional Meetings 20 (1.25) 
National Meetings 28 (1.8) 
Faculty in Center 16 
Number of Visitors 6 
27 
TABLE 2 

RESEARCH PROJECTS FUNDED EXTERNALLY 

REPORT PERIOD 2000-2001 

PROJECT DIRECTOR 
Frank Andrews 
Joseph Bartges 
David Brian 
TITLE OF GRANT 
The role of volatile fatty acids and calcium in 
gastric ulcer disease 
Pathogenesis ofacid injury in the non-glandular 
region of the equine stomach. 
Funding for a summer veterinary student and a 
clinical project: Determination of maintenance 
energy requirements ofclient-owned dogs 
Comparison of two dietary approaches for 
managing canine chronic renal failure 
Pentosan polysulfate sodium in the treatment of 
idiopathic feline lower urinary tract disease. 
Influence ofdiet on urine saturation with struvite in 
healthy cats 
Influence of diet on glycemic control in dogs with 
spontaneous insulin-dependent diabetes mellitus 
Influence of alkalinization on urinary saturation 
with calcium oxalate and struvite, and bone mineral 
density in cats 
APR studies 
Bovine coronavirus vector for mucosal immunity to 
phaemolytica leukotoxin 
Mechanism(s) ofcorona virus RNA replication and 
packaging 
FUNDING AGENCY 
Grayson-Jockey Club Research 
Foundation 
Grayson-Jockey Club Research 
Foundation 
Ralston Purina 
lams 
DVM Pharmaceuticals 
Ralston Purina 
Ralston Purina 
Morris Animal Foundation 
Hills Pet Nutrition 
USDA 
National Institute ofAllergies and 
Infectious Diseases 
TOTAL AWARDED 
$38,475 
04/01/01-03/31/02 
$37,110.00 
04/01/99-03/31/01 
$10,000.00 
OS/24/99-08/31/00 
$29,522.00 
04/01/99-07/01102 
$133,112.00 
09/12/97-08/31/01 
$9,594.00 
10/01197-10/31/00 
$6,093.00 
10/01/97-10/31/00 
$25,000.00 
09/01/97-03/31/00 
$13,500.00 
11/01197-10/31/04 
$140,000.00 
09/15/95-09/30/00 
$586,309.00 
07/01/96-06/30/0 I 
ESTIMATED 
EXPENDITURES 
$170.11 
$13,111.20 
$7,908.14 
$4,973.84 
$14,413.31 
$1,703.51 
$38.29 
$8,560.00 
136.13 
$44,103.33 
$117,969.08 
Mei-Zhen Cui Scientist development award 
James Godkin The role of retinol in oocyte maturation and early 
embryonic development. 
Stephen Kania Laboratory tests for vaccine development 
Ophidian paramyxovirus infection 
Analysis of coronavirus from cheetahs: Genetic 
analysis, epidemiology, and detection of infection 
Genetic Characterization of Coronavirus 
Alan Mathew Effects of environment and management on 
persistence of antibiotic resistance in bacteria from 
swine 
Effect ofdietary components on intestinal 
microflora 
Characterizing the origin and transfer ofantibiotic 
resistance 
Michael McEntee Effect ofn-3 and n-6 polyunsaturated fatty acids on 
growth and progression ofprostatic cancer in vivo 
In vivo effects ofresveratrol during early stages of 
intestinal tumorigenesis 
Role ofarachidonic acid and PGE2 as key 
mediators of intestinal tumorigenesis in vivo 
Chemoprevention of intestinal tumorigenesis in the 
Apc Minl+ mouse by the inhibition ofavB3 
integrin 
Role ofcycJooxygenase-l and/or -2 in the 
mechanism of intestinal tumorigenesis 
Jack Oliver Reactivity of bovine vasculature to Ergovaline and 
Ergine oftoxic tall fescue 
Sex hormone concentrations in dogs with adrenal 
hyperplasia syndrome treated with melatonin 
American Heart Association 
USDA 
Pfizer 
American Zoo & Aquarium Assoc 
American Zoo & Aquarium Assoc 
(Co-PI) 

Morris Animal Foundation (Co-PI) 

The International Life Science Institute 

lAMS 
National Pork Producers 
DOD-Army 
American Institute of Cancer Research 
American Institute ofCancer Research 

(Co-PI) 

Pharmacia (Co-PI) 

Pharmacia (Co-PI) 
USDA 
Morris Animal Foundation (Co-PI) 
$240,000.00 
oI/O 1/98-12/31/0 1 
$19,735.79 
$215,000.00 
09/01/99-08/3I/03 
$19,969.00 
$32,366.81 
7/15/99-7/31/01 
$28,081.36 
$16,900.00 
1% 1/98-9/30/00 $4,638.87 
$14,500.00 
9/1/00-8/31/0 I 
$0 
$14,500.00 
9/1/00-8/31/01 
$10,959.11 
$62,789.00 
09/0 I/99-08/3I/00 
$42,935.07 
$72,434.00 
04/I/00-07/1/02 
$49,212.52 
$31,690.00 
04/01/00-4/01/0 I 
$29,491.74 
$312,938.00 
04/15/00-05/14/03 
$16,865.44 
$75,952.00 
07/01/99-06/30/0 I 
$31 ,511.69 
$158,484.00 
7/99-6/01 
$130,540.28 
$24,739.00 
1% 1/00-1% 1/0 1 
$11 ,903.70 
$245,398.00 
1% 1/00-09/30/0 1 
$105,150.28 
$188,000.00 
10/01/97-09/30/00 
$28,875.94 
$8,189.00 
09/01/00-08/31/02 
$4,029.35 
Stephen Oliver Rapid, specific test for salmonella subtypes 
Reproductive performance and reproductive 
disorders in Jersey cows 
Development ofchronic streptococcus uberis 
intramammary infections in lactating dairy cows 
Evaluation of the Uterine Environment During 
Clinical Mastitis in Lactating Jersey Cows 
Evaluation and use ofBAMlFDA and rapid 
microbiological methods for on-farm surveys 
Evaluation ofsafety, specific immune responses, 
duration of immunity, and protection in dairy cows 
experimentally infected with Streptococcus uberis 
Molecular genetics of Streptococcus uberis as it 
relates to its ability to cause mastitis in dairy cow 
Efficacy of mastic ide for the treatment and 
prevention of teat lesions during the winter months 
Evaluation of safety, specific immune responses 
and protection in experimentally infected dairy 
cows following administration ofa S. uberis 
bacterin 
Does clinical mastitis reduce steroidogenic function 
ofthe preovulatory follicle in lactating jersey cows 
National Pork Producer's Council 
American Jersey Cattle Club 
Pharmacia and Upjohn 
American Jersey Cattle Club (Co-PI) 
Food and Drug Administration (Co-PI) 
Pfizer 
Pharmacia and Upjohn 
Sporicidin International 
Pfizer 
American Jersey Cattle Association 
(Co-PI) 
$29,150.00 $2,925.55 
06/01199-07/31/00 
$543,663.00 $124,512.64 
04/01199-04/01/00 
$56,258.00 $36,086.69 
01101199-12/31/00 
$5,500.00 $3,342.89 
04/01100-04/01101 
$475,610.00 $108,575.20 
09/30/98-09/29/01 
$237,376.00 $99,280.56 
10/25/00-10124/02 
$150,000.00 0 
08/01100-07131105 
$33,738.00 $6,393.53 
09/01100-08/31/01 
$85,000.00 $81,573.89 
07/12/00-04112/01 
$6,500.00 $29,254.00 
04/01101-04/02/02 
Barry Rouse 
Hildegard Schuller 
Terry Schultz 
Carla Sommardahl 
Herpes zosterfilization 
Immunity mechanisms in herpesvirus infections 
Mechanisms ofherpetic stromal keratitis 
Biodelivery sciences 
HSP peptide complexes as a putative vaccine 
against herpes simplex virus 
Vaccination against herpes simplex virus 
Transplacental pancreatic carcinogenesis by NNI 
FACS Vantage SE Cell Sorter/Flow Cytometer 
Development of a bioremediation risk assessment 
scheme 
Microbial transformation and molecular toxicology 
of estrogens 
The Role ofbioavailability in determining 
acceptable limits for the bioremediation of 
polychlorinated biphenyls 
Ecotoxicity oforganic chemicals 
Degradation ofnatural estrogens in wastewater 
treatment facilities 
Molecular analysis ofPKD in the TGN737RPW 
mouse 
Smith-Kline Biological 
National Institute ofAllergy and 
Infectious Diseases - Nlli 
National Eye Institute - Nlli 
Biodelivery Sciences 
Antigenics Agency 
National Institute ofAllergy and 
Infectious Diseases-Nlli 
National Institute of Health 
National Center for Research Resources 
US Environmental Protection Agency 
Water Resources Research Institute (Co-
PI) 
U.S. Department of Energy 
Proctor and Gamble 
University ofMississippi 
Nlli 
$124,746.00 $381.00 
open 
$1,656,250.00 $55,065.09 
01/01/01-12/31105 
$1,311,151 $181,077.35 
09/30/97-09/29/02 
$12,000.00 $0 
open 
$16,620.00 $28,860.87 
04/15/99-04/14/00 
$1 ,396,346.00 $230,828.19 
03/01/00-02/28/05 
$1,001,479.00 81,242.69 
08/01/96-07/31/01 
$150,000.00 $150,000.00 
04/01/00-03/31/01 
$59,199.00 $20,000.00 
09/94-09/98 
$295,334.00 $64,036.00 
12/07/98-12/06/00 
$441,037.00 $160,053.00 
01/01/97-05/31/00 
$6,600.00 0 
11/0199-10/31/01 
$25,400.00 $25,397.00 
09/01/97-10/31100 
$385,901.00 $96,897.45 
07/01197-07/01101 
Hwa-Chain Wang Pathway leads to apoptosis in SCR-transformed 
cells 
Nlli $517,520.00 
01101198-12/31102 
$57,2lO.75 
Biochemical evaluation of the functionality of 
mutated TBR-II and TBR-I receptors 
Ohio State University $192,453.00 
09/15/98-06/30/03 
$38,594.79 
Biomedical applications of Conrex enhancer Conrex $14,910.00 
11115/00-12114/01 
$5,183.96 
XueminXu Role of APOE in beta amyloid formation Sigma Kappa $30,000.00 
11101198-10/31100 
$4,754.14 
Role of apoE App processing Alzheimer's Association $80,000.00 
08/01198-12/31100 
$33,938.73 
Role of apolipoprotein in AD amyloid formation National Institute ofNeurological Disease 
and Stroke 
$677,968.00 
05/01199-04/30/02 
$lO6,766.67 
TOTALS $12,760,303.00 $2,579,219.71 
Schedule 7 
CENTERS OF EXCELLENCE/CENTERS OF EMPHASIS 
ACTUAL, PROPOSED, AND REQUESTED BUDGET 
Institution ~ol~le~g~e~m~V~e~re~r~ln~a~ry~Me~d~~~ln~e~______________________ Cenmr Livestock and Human Health 
'0 :" .~;G" ~1:"• 
2000-2001 Actual 2001-2002 PropoHcI 2002-2003 Req~ " ·It 
'.'7~ , .:'
,;F.1 .f~"~~ " 
Matching Appropr. Teul Matching ApprOpr. Total Matching !!" Appropr, ". T~ , 
Expenditures 265,250 530,500 795,750 265,250 530,500 795,750 278,082 557,456 835,538 
Salaries 
Faculty 23,318 46,637 69,955 31 ,712 63,425 95,137 31 ,672 63,492 95,164 
Other Professional 90,991 181 ,983 272,974 26,490 52,979 79,469 81 ,182 162,741 243,923 
Clericall Supporting 13,644 27,289 40,933 55,879 111 ,758 167,637 10,250 20,548 30,798 
Assistantships 21 ,937 43,874 65,810 22,400 44,800 67,200 21,015 42,128 63,143 
Total Salaries 149,891 299,782 449,673 136,481 272,962 409,443 144,119 288,909 433,028 
Fringe Benefits 34,225 68,451 102,676 26,483 52,967 79,450 33,145 66,289 99,434 
!(> "._', :'-, '- .' I '"',~ ~>."",,;.. 
Tdal Personnel 184,116 368,233 552,3.0 I', 162,964 325,929 488,893 -f~177;" 
'1(' 
"". 35$,1" ~, 532;*~ ' 
Non.personnel 
Travel 3,114 6,229 9,343 1,360 2,720 4,080 0 
Softwcre 2,270 4,541 6,811 0 0 
Books & Journals 64 129 193 0 0 
Other Supplies 42,674 85,348 128,022 53,441 106,881 160,322 34,334 68,824 103,158 
Equipment 48,949 97,897 146,846 50,000 100,000 150,000 52,639 105,279 157,918 
Maintenance 13,348 26,694 40,042 6,167 12,333 18,500 14,000 28,000 42,000 
Scholarships 1,920 3,838 5,758 2,500 5,000 7,500 0 
Consultants 0 0 0 
Renovation 0 0 0 
Other (Specify) 0 0 0 
Cont&SpSvc 825 1,650 2,476 0 0 
Printing & Duplatlon 52 103 155 0 0 
Publations , Reports 97 194 291 0 0 
'~ I'" 
., -~ "*-. >~. ~ :!o~'. ~. , :1<1' ',~" 
Tdal Non-Personnel 113,3t2 226.124 331,131 113,468 228,134' , 34OAOZ 1QO,i73 fii 202,1~ . -.076 
." ", '11557,_GRAND TOTAL 217,421 594,851 892,215 276,432 552,883 m.2.s ;278,2J7 _,,~ ~538 
Revenue 
New State Appropriation 530,500 530,500 530,500 530,500 557,025 557,025 
IUlrTyOl.'er ::state 
Appropriation 64,356 64,356 22,363 22,363 0 
New Matching Funds 265,250 265,250 265,250 265,250 278,513 278,513 
\"arryover!rom Pre\l1OUS 
Matching Funds 32,178 32,178 11,182 11,182 0 
. , ' ­
-I '" 
" [..,:f,.. I ' - '. "'i 
Total Revenue ·297~ 6M.8I6. 892,284 27&,q2 > 552,863 829,295 1 · ~,3 , ~,Cl25 . ". 8IlI,sae 

